Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 20;8:131. doi: 10.1038/s41523-022-00499-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A PFS duration in all lines of therapy combined. B OS duration in all lines of therapy combined. C PFS duration on 1L CDK4/6is plus AI. D OS duration on 1L CDK4/6is plus AI. E PFS duration on 1L CDK4/6is plus FUL. F OS duration on 1L CDK4/6is plus FUL. G PFS duration on 2L+ CDK4/6is plus FUL. H OS duration on 2L+ CDK4/6is plus FUL. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, mixed mixed invasive ductal and lobular carcinoma, PFS progression-free survival, OS overall survival, CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, 1L, first line, 2L+ , second line and beyond, AI aromatase inhibitor, FUL fulvestrant, HR+, hormone receptor-positive, HER2− human epidermal growth factor receptor 2-negative.